Advancedmolecular
Telomeres and the End-Replication Problem
Overview
Linear chromosomes face the end-replication problem: lagging-strand synthesis cannot copy the extreme 3' end, so telomeres (TTAGGG repeats in vertebrates) shorten with each division. Telomerase, a ribonucleoprotein with its own RNA template, extends telomeres in stem and germ cells; most somatic cells lack it and senesce after ~50 divisions (the Hayflick limit). Cancer cells reactivate telomerase to achieve immortality.
Learning objectives
- Explain the end-replication problem
- Describe telomere structure and telomerase mechanism
- Connect telomere shortening to aging
- Explain telomerase in cancer
The end-replication problem
When the final lagging-strand primer at the chromosome tip is removed, no upstream 3'-OH exists to fill the gap, so the new strand ends short. Each division thus erodes the telomere by ~50-200 bp. Without a solution, essential genes would eventually be chewed away.
The 5' end of each new lagging strand cannot be completed: chemistry, not sloppiness.
Telomeres and telomerase
Telomeres are TTAGGG repeats (vertebrates) ending in a 3' overhang tucked into a t-loop, protected by shelterin proteins. Telomerase carries its own RNA template (3'-CAAACCCCAAC-5' in humans) and extends the 3' overhang by reverse transcription; primase-polymerase then fills the complement. Discovered by Greider and Blackburn in Tetrahymena (Nobel 2009).
It copies its internal RNA into DNA: the cell's built-in template for chromosome ends.
Aging and the Hayflick limit
Human somatic cells divide ~40-60 times before telomeres trigger senescence (p53/p21) or crisis: the Hayflick limit. Short telomeres mark aging and predict mortality in epidemiological studies. Telomerase is active in stem cells, germ cells, and activated lymphocytes, but silenced in most soma.
Short telomeres associate with aging, but whether lengthening them safely extends healthspan is unproven and risky.
Cancer's immortality trick
~85-90% of cancers reactivate telomerase (often via TERT promoter mutations); most of the rest use ALT (alternative lengthening, recombination-based). Telomere maintenance is a hallmark of cancer: without it, tumors would senesce. Telomerase inhibitors are an active therapeutic strategy.
Every long-lived cell lineage, from stem cells to cancers, must solve the end-replication problem.
Key points
- Lagging-strand primer removal shortens chromosome ends each division
- Telomerase extends TTAGGG repeats using its own RNA template
- Somatic telomere loss limits divisions (Hayflick limit ~50)
- Most cancers reactivate telomerase; the rest use ALT
Common misconceptions
✓ Truth: Shortening is a precise consequence of primer removal at chromosome ends, not random error.
✓ Truth: Telomerase activation is oncogenic: the same immortality serves cancer. Any therapy must thread this needle.
Practice questions
Q1. The end-replication problem arises because
- Helicase is slow
- The terminal lagging-strand primer leaves an unfillable gap
- Telomeres are too long
- Ligase is absent
No upstream 3'-OH exists to extend after the last primer is removed.
Q2. Human telomere repeats are
- AATAAA
- TTAGGG
- TATA
- CGG
Vertebrate telomeres are tandem TTAGGG repeats.
Q3. Most cancer cells maintain telomeres by
- Ignoring the problem
- Reactivating telomerase (or ALT)
- Circularizing chromosomes
- Shortening faster
~85-90% reactivate telomerase; the remainder use recombination-based ALT.
Click a question to reveal the answer and explanation.
Frequently asked questions
What is the Hayflick limit?
The ~40-60 division cap for cultured human somatic cells, imposed largely by telomere attrition.
How does ALT differ from telomerase?
ALT lengthens telomeres by homologous recombination between telomeric repeats, without telomerase enzyme.
Why do germ cells keep telomerase active?
The germline must reset telomere length each generation; otherwise species would age into extinction within generations.